Exhibit 99.1 Genmab Announces Financial Results for the First Nine Months of 2023 November 7, 2023 Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2023 Highlights ● Epcoritamab (TEPKINLY®) was granted conditional marketing authorization by the European Commission (EC) to treat adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy ● Epcoritamab (EPKINLY™) was approved by the Japan Ministry of Health, Labour and W ...